ProfileGDS5678 / 1448604_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 85% 85% 86% 86% 86% 87% 85% 84% 89% 89% 88% 88% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.661487
GSM967853U87-EV human glioblastoma xenograft - Control 26.4698985
GSM967854U87-EV human glioblastoma xenograft - Control 36.4306285
GSM967855U87-EV human glioblastoma xenograft - Control 46.7325886
GSM967856U87-EV human glioblastoma xenograft - Control 56.5233886
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3705386
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4967787
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3815685
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1809584
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.9877689
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9242589
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8446988
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.830588
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7194687